Validation of incorporating flurbiprofen into the Pittsburgh cocktail

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 3, 2006, Pages 257-263

  Zgheib, Nathalie K ^a   Frye, Reginald F ^a   Tracy, Timothy S ^a   Romkes, Marjorie ^a   Branch, Robert A ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DAPSONE; DEBRISOQUINE; DRUG METABOLIZING ENZYME; FLURBIPROFEN; MEPHENYTOIN;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; LATIN SQUARE DESIGN; LIVER MICROSOME METABOLISM; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; URINALYSIS; VALIDATION STUDY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CAFFEINE; CHLORZOXAZONE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; DEBRISOQUIN; DRUG THERAPY, COMBINATION; FEMALE; FLURBIPROFEN; GENOTYPE; HUMANS; ISOENZYMES; MALE; MEPHENYTOIN; MIDDLE AGED;

EID: 33748178314     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.06.005     Document Type: Article

References (33)

1. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 (2005) 2211-2221
2. Frye R.F. Probing the world of cytochrome p450 enzymes. Mol Interv 4 (2004) 157-162
3. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
4. Breimer D.D., and Schellens J.H. A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 11 (1990) 223-225
5. Black C., May G., Csuka M.E., Lupoli S., Wilkinson G.R., and Branch R.A. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease. Clin Pharmacol Ther 52 (1992) 659-667
6. Frye R.F., Matzke G.R., Adedoyin A., Porter J.A., and Branch R.A. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62 (1997) 365-376
7. Fuhr U., and Rost K.L. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4 (1994) 109-116
8. Wedlund P.J., Aslanian W.S., McAllister C.B., Wilkinson G.R., and Branch R.A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36 (1984) 773-780
9. Meyer U.A., Skoda R.C., and Zanger U.M. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther 46 (1990) 297-308
10. Frye R.F., Adedoyin A., Mauro K., Matzke G.R., and Branch R.A. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 38 (1998) 82-89
11. May D.G., Porter J.A., Uetrecht J.P., Wilkinson G.R., and Branch R.A. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 48 (1990) 619-627
12. Greenblatt D.J., Von Moltke L.L., Luo Y., Perloff E.S., Horan K.A., Bruce A., et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 46 (2006) 214-221
13. Lasker J.M., Wester M.R., Aramsombatdee E., and Raucy J.L. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353 (1998) 16-28
14. Lee C.R., Pieper J.A., Frye R.F., Hinderliter A.L., Blaisdell J.A., and Goldstein J.A. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 58 (2003) 791-794
15. Takahashi H., Kashima T., Nomizo Y., Muramoto N., Shimizu T., Nasu K., et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 63 (1998) 519-528
16. Tassaneeyakul W., Birkett D.J., Pass M.C., and Miners J.O. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br J Clin Pharmacol 42 (1996) 774-778
17. Yun C.H., Lee H.S., Lee H., Rho J.K., Jeong H.G., and Guengerich F.P. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 23 (1995) 285-289
18. Tracy T.S., Rosenbluth B.W., Wrighton S.A., Gonzalez F.J., and Korzekwa K.R. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49 (1995) 1269-1275
19. Tracy T.S., Marra C., Wrighton S.A., Gonzalez F.J., and Korzekwa K.R. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52 (1996) 1305-1309
20. Lee C.R., Pieper J.A., Frye R.F., Hinderliter A.L., Blaisdell J.A., and Goldstein J.A. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43 (2003) 84-91
21. Zgheib N.K., Frye R.F., Tracy T.S., Romkes M., and Branch R.A. Evaluation of flurbiprofen urinary ratios as selective in vivo indexes for CYP2C9 activity. Br J Clin Pharmacol (2006) In press
22. Hutzler J.M., Frye R.F., and Tracy T.S. Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J Chromatogr B Biomed Sci Appl 749 (2000) 119-125
23. Hayashi S., Watanabe J., and Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 110 (1991) 559-565
24. Watanabe J., Hayashi S., Nakachi K., Imai K., Suda Y., Sekine T., et al. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 18 (1990) 7194
25. Chow S.C., and Liu J.P. Design and analysis of bioavailability and bioequivalence studies (1992), Marcel Dekker, New York
26. Tucker G.T., Houston J.B., and Huang S.M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18 (2001) 1071-1080
27. Hutzler J.M., Frye R.F., Korzekwa K.R., Branch R.A., Huang S.M., and Tracy T.S. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci 14 (2001) 47-52
28. Miners J.O., and Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45 (1998) 525-538
29. Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56 (1998) 243-251
30. Jetter A., Kinzig-Schippers M., Skott A., Lazar A., Tomalik-Scharte D., Kirchheiner J., et al. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60 (2004) 165-171
31. Gill H.J., Tingle M.D., and Park B.K. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40 (1995) 531-538
32. Fleming C.M., Persad R., Kaisary A., Smith P., Adedoyin A., Porter J., et al. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 4 (1994) 199-207
33. Palmer J.L., Scott R.J., Gibson A., Dickins M., and Pleasance S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 52 (2001) 555-561